Renal Anemia Market Overview
The kidneys produce erythropoietin (EPO), an important hormone responsible for red blood cell production. In kidney disease, the kidneys lose the ability to make sufficient EPO, which leads to a drop in red blood cell count, thereby causing anemia. It is common for people with kidney disease to develop anemia. It is estimated that around 500,000 adult patient on dialysis in the United States are affected by anemia due to chronic kidney disease. Thus, the rising cases of chronic kidney diseases are driving the renal anemia market growth. The growing focus on early detection and treatment is increasing the demand for effective renal anemia therapies and aiding the overall market expansion. Moreover, the rising introduction of novel therapeutic options such as HIF prolyl hydroxylase inhibitors, the growth in clinical trials and drug approvals, and the increasing healthcare expenditure are some of the factors impacting the market dynamics.
Key Findings
- Chronic kidney disease, in which anemia is a common complication, affects roughly 10% of the general population globally. The increasing prevalence of chronic kidney disease is expected to fuel the market growth.
- In March 2024, Akebia Therapeutics, a fully integrated biopharmaceutical company, announced the FDA approval of its Vafseo (vadadustat) tablets indicated for the treatment of anemia caused by chronic kidney disease in adults who have undergone dialysis for at least three months. The surge in such drug approvals by the regulatory bodies is poised to elevate the market value.
- The rising advancements in diagnostics and monitoring of anemia in chronic kidney disease patients are significant market trends that are likely to increase the rate of early and accurate detection of the disease.
Renal Anemia Market Demand Drivers
Anemia is considered a common complication of chronic kidney disease (CKD) and is linked with an increased risk of progression of the disease, hospitalization, and reduced quality of life, among other adverse outcomes. According to the American Kidney Fund, around 35.5 million Americans have kidney disease and nearly 808,000 of them are living with kidney failure. Further, it is estimated that 557,000 Americans are receiving dialysis. The increasing prevalence of chronic kidney disease and the growing number of patients undergoing dialysis are one of the primary factors driving the market demand for advanced treatments. Additionally, the rising advancements in diagnostic technologies and improvements in healthcare facilities are anticipated to augment the demand for the market in the coming years.
Renal Anemia Market Segmentation Analysis
The Type Segment is Poised to Cover a Significant Market Share in the Forecast Period
Based on type, the market segmentation includes iron deficiency anemia, vitamin B12 deficiency anemia, folate deficiency anemia, aplastic anemia, sickle cell anemia, and others. Iron deficiency anemia is one of the most common forms of anemia, even in patients with chronic kidney disease. Oral or intravenous iron supplements are often recommended to the patient depending on the severity of the deficiency. A combination treatment of intravenous iron and erythropoiesis-stimulating agents (ESAs) usually proves effective for people suffering from renal anemia.
The market report also offers insights based on treatment type, route of administration, end user, and region.
Renal Anemia Market: Competitive Landscape
- In October 2023, leading Indian pharmaceutical companies Zydus Lifesciences and Sun Pharmaceutical Industries struck a licensing agreement that will allow them to co-market an oral treatment of anemia caused by chronic kidney disease called Desidustat.
- In February 2023, British multinational pharma GlaxoSmithKline LLC’s Jesduvroq tablet (daprodustat) was approved by the FDA, becoming the first oral therapy for anemia caused by chronic kidney disease for adults on dialysis for at least four months.
- Other players involved in the market include AstraZeneca, F. Hoffmann-La Roche Ltd, Astellas Pharma, Amgen Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Sanofi, AbbVie Inc., and Pfizer.
Renal Anemia Market Analysis by Region
The United States Represents a Significant Market Share
The market report offers insight into various geographical locations, including the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States leads the market share which can be attributed to the rising burden of chronic kidney disease and heightened awareness about anemia in patients suffering from kidney diseases. The market also benefits from significant investments in clinical research to advance treatment options. Additionally, the presence of a well-established healthcare system and a favorable regulatory environment are some of the factors which are poised to boost the market growth in the region.
Key Offerings of the Report
- The EMR report gives an overview of the market for renal anemia for the time span of (2017-2023) and (2024-2032).
- The report also offers historical (2017-2023) and forecast (2024-2032) market information for the type, treatment type, route of administration, end user, and region of the market.
- The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.
About Us
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Contact Us
Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
